Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis

High CCR5 expression in natalizumab-associated progressive multifocal leukoencephalopathy immune reconstitution inflammatory syndrome supports treatment with the CCR5 inhibitor maraviroc

(2015) Lidia Stork et al.   ACTA NEUROPATHOLOGICA

Infection Risk in Patients on Multiple Sclerosis Therapeutics

(2015) Eric M. Williamson et al.   CNS DRUGS

Treatment of progressive multifocal leukoencephalopathy–immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab

(2015) Z. Calic et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Rituximab treatment did not aggravate ongoing progressive multifocal leukoencephalopathy in a patient with multiple sclerosis

(2015) F. Asztely et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients

(2015) Francesca Rossi et al.   MOLECULAR AND CELLULAR PROBES

PML in a Patient without Severe Lymphocytopenia Receiving Dimethyl Fumarate

(2015) Dennis J. Nieuwkamp et al.   NEW ENGLAND JOURNAL OF MEDICINE

PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate

(2015) Thorsten Rosenkranz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy

(2014) Tatiana Plavina et al.   ANNALS OF NEUROLOGY

Natalizumab treatment for multiple sclerosis: updates and considerations for safer treatment in JCV positive patients

(2014) Luiz Henrique da Silva Nali et al.   ARQUIVOS DE NEURO-PSIQUIATRIA

Monoclonal Antibodies and Progressive Multifocal Leukoencephalopathy

(2014) Daniel L. Keene et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Immunological Mechanism of Action and Clinical Profile of Disease-Modifying Treatments in Multiple Sclerosis

(2014) Renaud A. Du Pasquier et al.   CNS DRUGS

Dimethyl fumarate for treating relapsing multiple sclerosis

(2014) William Sheremata et al.   Expert Opinion On Drug Safety

MRI pattern in asymptomatic natalizumab-associated PML

(2014) Mike P Wattjes et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Minimal supportive treatment in natalizumab-related PML in a MS patient

(2014) P. H. Lalive et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy

(2014) A Vennegoor et al.   Multiple Sclerosis Journal

Recurrence of disease activity after repeated Natalizumab withdrawals

(2014) Laura Ferrè et al.   NEUROLOGICAL SCIENCES

Natalizumab to fingolimod washout in patients at risk of PML: When good intentions yield bad outcomes

(2014) G. Giovannoni et al.   NEUROLOGY

Progressive multifocal leukoencephalopathy and JC Virus-related disease in modern neurology practice

(2014) Robert L. Carruthers et al.   Multiple Sclerosis and Related Disorders

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients

(2014) Tuan Dong-Si et al.   Annals of Clinical and Translational Neurology

Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis

(2013) Joshua J. Chalkley et al.   Current Neurology and Neuroscience Reports

Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial

(2013) C. Bozic et al.   EUROPEAN JOURNAL OF NEUROLOGY

A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification

(2013) Peter Lee et al.   JOURNAL OF CLINICAL VIROLOGY

PML in a Patient Treated with Dimethyl Fumarate from a Compounding Pharmacy

(2013) Bob W. van Oosten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Manufacturer's Response to Case Reports of PML

(2013) Marianne T. Sweetser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab in Relapsing and Progressive Forms of Multiple Sclerosis: A Systematic Review

(2013) Tamara Castillo-Trivino et al.   PLoS One

Glatiramer acetate for treatment of relapsing–remitting multiple sclerosis

(2012) Kenneth P Johnson   Expert Review of Neurotherapeutics

Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab

(2012) Eavan M. Mc Govern et al.   JOURNAL OF NEUROLOGY

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

(2012) Per Soelberg Sørensen et al.   Multiple Sclerosis Journal

Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort

(2012) A. K. Trampe et al.   NEUROLOGY

Impairment of JCV-specific T-cell response by corticotherapy: Effect on PML-IRIS management?

(2012) C. Antoniol et al.   NEUROLOGY

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY-1

(2011) Carmen Bozic et al.   ANNALS OF NEUROLOGY

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway

(2011) Ralf A. Linker et al.   BRAIN

Age-Specific Seroprevalence of Merkel Cell Polyomavirus, BK Virus, and JC Virus

(2011) Raphael P. Viscidi et al.   Clinical and Vaccine Immunology

MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy: Figure 1

(2011) Rémy Phan-Ba et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Immune reconstitution inflammatory syndrome in natalizumab-associated PML

(2011) I. L. Tan et al.   NEUROLOGY

Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy

(2011) P. Vermersch et al.   NEUROLOGY

Natalizumab and Progressive Multifocal Leukoencephalopathy

(2010) Clemens Warnke et al.   ARCHIVES OF NEUROLOGY

Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis

(2010) Jerold Chun et al.   CLINICAL NEUROPHARMACOLOGY

Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians

(2010) A. Antonsson et al.   JOURNAL OF GENERAL VIROLOGY

Human Polyomavirus JC (JCV) Infection of Human B Lymphocytes: A Possible Mechanism for JCV Transmigration across the Blood‐Brain Barrier

(2010) Moti L. Chapagain et al.   JOURNAL OF INFECTIOUS DISEASES

JC Virus Latency in the Brain and Extraneural Organs of Patients with and without Progressive Multifocal Leukoencephalopathy

(2010) C. S. Tan et al.   JOURNAL OF VIROLOGY

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

(2010) David B Clifford et al.   LANCET NEUROLOGY

Thalamofrontal neurodevelopment in new-onset pediatric idiopathic generalized epilepsy

(2010) D. T. Pulsipher et al.   NEUROLOGY

Is maraviroc beneficial in paradoxical progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome management?

(2009) Guillaume Martin-Blondel et al.   AIDS

Mirtazapine Use in Human Immunodeficiency Virus–Infected Patients With Progressive Multifocal Leukoencephalopathy

(2009) Deanna Cettomai et al.   ARCHIVES OF NEUROLOGY

PML-IRIS in patients with HIV infection: Clinical manifestations and treatment with steroids

(2009) K. Tan et al.   NEUROLOGY